Our manufacturing footprint — 15 world-class facilities spread across India, the U.S., Brazil and Mexico — are designed to deliver the promise of caring that Lupin has come to symbolise – that no patient shall be denied access to high-quality, affordable medicines.

Mumbai, December 14, 2021:Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Goa manufacturing facility, after the inspection of the facility in September 2021.

Mumbai, July 27, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received correspondence from the US FDA that it has now addressed the concerns raised in the Warning Letter for its facilities in Goa and Pithampur Unit-2, Indore.

Jul 29, 2023 · Lupin, a leading pharmaceutical company, has successfully addressed the concerns raised in the U.S. Food and Drugs Administration (USFDA) warning letter for its manufacturing facilities in Goa and Pithampur Unit-2, Indore.

Dec 17, 2021 · Global pharma major Lupin Limited (Lupin) announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Goa manufacturing facility, after the inspection of the facility in September 2021.

Sep 23, 2021 · Pharma-major Lupin has received seven observations from the USFDA after the latter carried an inspection at the company’s Goa facility in India. The US health regulator carried the inspection between September 10 to September 18, …

Mumbai, December 14, 2021: Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Goa manufacturing facility, after the inspection of the facility in September 2021.

Jul 27, 2023 · Lupin on Thursday said it has received correspondence from the USFDA that it has now addressed the concerns raised in the Warning Letter for its facilities in Goa and Pithampur Unit-2, Indore.

Dec 14, 2021 · Lupin today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (FDA) for its Goa manufacturing facility, after the inspection of the facility in September 2021.

Sep 19, 2021 · Mumbai-based drugmaker said on Sunday that its Goa facility has received seven observations from the US drug regulator. At present, five sites of Lupin either have warning letters of Official Action Indicated (OAI) status from the US Food and Drug Administration.